United States: These 41 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in the United States

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "United States: These 41 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can JUXTAPID (lomitapide mesylate) generic drug versions launch?

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: United States Patent Patent 8,618,135

JUXTAPID is a drug marketed by Chiesi. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

When can SMOFLIPID 20% (fish oil; medium chain triglycerides; olive oil; soybean oil) generic drug versions launch?

Generic name: fish oil; medium chain triglycerides; olive oil; soybean oil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SMOFLIPID 20% is a drug marketed by Fresenius Kabi Usa.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.

When can PIZENSY (lactitol) generic drug versions launch?

Generic name: lactitol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 12, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIZENSY is a drug marketed by Braintree Labs. There is one patent protecting this drug.

The generic ingredient in PIZENSY is lactitol. There are four drug master file entries for this API. Additional details are available on the lactitol profile page.

When can IXEMPRA KIT (ixabepilone) generic drug versions launch?

Generic name: ixabepilone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: United States Patent Patent 7,312,237

IXEMPRA KIT is a drug marketed by R-pharm Us Llc. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-six countries.

See drug price trends for IXEMPRA KIT.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this API. Additional details are available on the ixabepilone profile page.

When can DUAKLIR PRESSAIR (aclidinium bromide; formoterol fumarate) generic drug versions launch?

Generic name: aclidinium bromide; formoterol fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

DUAKLIR PRESSAIR is a drug marketed by Covis. There are four patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty-six countries.

See drug price trends for DUAKLIR PRESSAIR.

The generic ingredient in DUAKLIR PRESSAIR is aclidinium bromide; formoterol fumarate. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the aclidinium bromide; formoterol fumarate profile page.

When can TUDORZA PRESSAIR (aclidinium bromide) generic drug versions launch?

Generic name: aclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

TUDORZA PRESSAIR is a drug marketed by Covis. There are four patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty-six countries.

See drug price trends for TUDORZA PRESSAIR.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the aclidinium bromide profile page.

When can BARHEMSYS (amisulpride) generic drug versions launch?

Generic name: amisulpride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BARHEMSYS is a drug marketed by Acacia. There are five patents protecting this drug.

This drug has sixty-eight patent family members in twenty-seven countries.

See drug price trends for BARHEMSYS.

The generic ingredient in BARHEMSYS is amisulpride. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amisulpride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2025
Generic Entry Controlled by: United States Patent Patent 9,522,919

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can SANCUSO (granisetron) generic drug versions launch?

Generic name: granisetron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 22, 2025
Generic Entry Controlled by: United States Patent Patent 7,608,282

SANCUSO is a drug marketed by Cumberland. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in thirty-one countries. There has been litigation on patents covering SANCUSO

See drug price trends for SANCUSO.

The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

When can XARELTO (rivaroxaban) generic drug versions launch?

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: United States Patent Patent 7,157,456

XARELTO is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

When can TLANDO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TLANDO is a drug marketed by Verity. There are thirteen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-six patent family members in fifteen countries.

See drug price trends for TLANDO.

The generic ingredient in TLANDO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can XELSTRYM (dextroamphetamine) generic drug versions launch?

Generic name: dextroamphetamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

XELSTRYM is a drug marketed by Noven Pharms Inc. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in twelve countries. There has been litigation on patents covering XELSTRYM

See drug price trends for XELSTRYM.

The generic ingredient in XELSTRYM is dextroamphetamine. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dextroamphetamine profile page.

When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch?

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2025
Generic Entry Controlled by: United States Patent Patent 10,947,544

IZERVAY is a drug marketed by Astellas. There are nine patents protecting this drug.

This drug has one hundred and two patent family members in twenty-seven countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.